New drug nearly doubles survival in pancreatic cancer’s deadliest cases

A phase 3 trial found that daraxonrasib — a once-daily oral drug targeting the KRAS mutation present in 90% of pancreatic tumors — nearly doubled median survival when combined with chemotherapy. Stanford oncologists called it “truly earth-shattering.” The FDA has flagged it as a high-priority therapy and fast-tracked its review.